
https://www.science.org/content/blog-post/remember-when-we-were-going-eliminate-deaths-cancer
# Article Title (February 2012)

## 1. SUMMARY
The article criticizes former FDA commissioner Andrew von Eschenbach's 2003 announcement, made when he was director of the National Cancer Institute (NCI), to "eliminate death and suffering" from cancer by 2015. The author notes that as of 2012—with three years left to the deadline—it was already clear the goal would not be met. The piece argues that such aspirational targets are unhelpful because cancer is not a single disease but "a constellation of thousands of diseases," making a 2015 elimination target unrealistic.

The article also acknowledges Eschenbach's more substantive view: that genomics would allow researchers to reverse-engineer why some patients respond (e.g., by identifying EGFR receptor mutations) and accelerate therapy development beyond the "hit-and-miss approach" of the past. The author agrees with this approach in principle but disputes the timeline and scale, pointing out that biology is "really, really big," full of dead ends, and that progress comes from smart, persistent investigation rather than slogans.

## 2. HISTORY
In the period following the article's publication (2012 to present), cancer research and treatment did move substantially toward the mechanistic, genomics-driven approach Eschenbach advocated, but without meeting—or coming close to—the "eliminate death and suffering by 2015" goal.

The overall U.S. cancer death rate continued its long, gradual decline of roughly 1–2% per year, falling from about 170 deaths per 100,000 population in 2012 to around 146 per 100,000 by 2021. Age-adjusted mortality has trended downward for decades, with no sharp acceleration around 2015. In absolute terms, the number of cancer deaths remained roughly level or increased slightly due to demographic aging, before beginning to decline in 2017–2019 and then ticking upward again during the COVID-19 pandemic.

Genomics-driven targeted therapies did deliver meaningful advances for specific populations. Examples include:
- Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab), which achieved durable responses in subsets of multiple tumor types.
- CAR-T cell therapies (e.g., tisagenlecleucel, axicabtagene ciloleucel), approved beginning in 2017 for certain blood cancers.
- Expansion of targeted kinase inhibitors and monoclonal antibodies guided by biomarkers.

However, these advances were concentrated in particular cancers (e.g., lung, melanoma, some leukemias/lymphomas) and typically benefited only subsets of patients with specific biomarkers. Broadly effective, curative treatments remained elusive for most solid tumors, and acquired resistance limited long-term remissions. The new modalities did not eliminate cancer deaths at the population level by 2015 or thereafter.

No evidence suggests policy or implementation changes were driven by the 2015 target; research funding and drug development proceeded along established incremental pathways rather than a focused "elimination" effort.

## 3. PREDICTIONS
- **Prediction implied by goal statement (2003):** "eliminate death and suffering" from cancer by 2015.
  - **Outcome:** Not achieved. Cancer death rates continued their gradual decline and did not approach elimination. Incidence and mortality remained substantial public health challenges well beyond 2015.

- **Eschenbach's mechanism prediction (2006):** Genomics tools would enable reverse-engineering of patient responses (e.g., finding EGFR mutations in responding patients) and end reliance on decades of "hit-and-miss" trial-and-error.
  - **Outcome:** Partially validated in direction but over-optimistic on timeline and scope. Precision oncology and biomarker-guided trials did become central to drug development, and many targeted therapies received FDA approval and clinical uptake. However, the heterogeneity of cancer meant that identifying drivers did not always yield cures, resistance remained common, and the practice continued to involve extensive trial-and-error, though more hypothesis-driven than before.

- **Author's counter-prediction:** The ocean of cancer biology is "really, really big"; progress requires "smart and persistent" investigation, not slogans, and eliminating deaths "any time soon" will not happen.
  - **Outcome:** Largely borne out. Steady but slow progress continued in specific domains; no sudden, population-wide elimination occurred. Research complexity and dead ends persisted, and no magic bullet emerged to replace careful, iterative science.

## 4. INTEREST
Rating: **7/10**
The article is highly germane because it confronts a recurring tension between aspirational public messaging and realistic timelines in biomedicine, and because it highlights the genuine pivot to genomics-driven oncology that was underway.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20120223-remember-when-we-were-going-eliminate-deaths-cancer.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_